MEDINCELL SA (MEDCL.PA) Stock Fundamental Analysis
Europe - Euronext Paris - EPA:MEDCL - FR0004065605 - Common Stock
24.02 EUR
-3.74 (-13.47%)
Taking everything into account, MEDCL scores 4 out of 10 in our fundamental rating. MEDCL was compared to 55 industry peers in the Pharmaceuticals industry. The financial health of MEDCL is average, but there are quite some concerns on its profitability. MEDCL is valued quite expensive, but it does show an excellent growth.
1. Profitability
1.1 Basic Checks
- MEDCL had negative earnings in the past year.
- MEDCL had a negative operating cash flow in the past year.
- In the past 5 years MEDCL always reported negative net income.
- MEDCL had negative operating cash flow in 4 of the past 5 years.
1.2 Ratios
- With a Return On Assets value of -26.75%, MEDCL is not doing good in the industry: 80.00% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -26.75% | ||
| ROE | N/A | ||
| ROIC | N/A |
ROA(3y)-65.75%
ROA(5y)-56.62%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- MEDCL has a Gross Margin of 85.42%. This is amongst the best in the industry. MEDCL outperforms 92.73% of its industry peers.
- In the last couple of years the Gross Margin of MEDCL has grown nicely.
- The Profit Margin and Operating Margin are not available for MEDCL so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 85.42% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y14.72%
GM growth 5Y7.65%
2. Health
2.1 Basic Checks
- MEDCL does not have a ROIC to compare to the WACC, probably because it is not profitable.
- MEDCL has more shares outstanding than it did 1 year ago.
- Compared to 5 years ago, MEDCL has more shares outstanding
- Compared to 1 year ago, MEDCL has an improved debt to assets ratio.
2.2 Solvency
- An Altman-Z score of 5.25 indicates that MEDCL is not in any danger for bankruptcy at the moment.
- The Altman-Z score of MEDCL (5.25) is better than 74.55% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Altman-Z | 5.25 |
ROIC/WACCN/A
WACC7.78%
2.3 Liquidity
- MEDCL has a Current Ratio of 2.88. This indicates that MEDCL is financially healthy and has no problem in meeting its short term obligations.
- With an excellent Current ratio value of 2.88, MEDCL belongs to the best of the industry, outperforming 89.09% of the companies in the same industry.
- MEDCL has a Quick Ratio of 2.88. This indicates that MEDCL is financially healthy and has no problem in meeting its short term obligations.
- Looking at the Quick ratio, with a value of 2.88, MEDCL belongs to the top of the industry, outperforming 92.73% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.88 | ||
| Quick Ratio | 2.88 |
3. Growth
3.1 Past
- MEDCL shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 43.15%, which is quite impressive.
- MEDCL shows a strong growth in Revenue. In the last year, the Revenue has grown by 166.31%.
- Measured over the past years, MEDCL shows a very strong growth in Revenue. The Revenue has been growing by 54.88% on average per year.
EPS 1Y (TTM)43.15%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%2.92%
Revenue 1Y (TTM)166.31%
Revenue growth 3Y83.86%
Revenue growth 5Y54.88%
Sales Q2Q%34.66%
3.2 Future
- MEDCL is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 49.90% yearly.
- MEDCL is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 39.81% yearly.
EPS Next Y59.91%
EPS Next 2Y66.38%
EPS Next 3Y47.87%
EPS Next 5Y49.9%
Revenue Next Year13.44%
Revenue Next 2Y54.94%
Revenue Next 3Y67.72%
Revenue Next 5Y39.81%
3.3 Evolution
- Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
- MEDCL reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
- With a Price/Forward Earnings ratio of 40.91, MEDCL can be considered very expensive at the moment.
- Compared to the rest of the industry, the Price/Forward Earnings ratio of MEDCL indicates a slightly more expensive valuation: MEDCL is more expensive than 70.91% of the companies listed in the same industry.
- The average S&P500 Price/Forward Earnings ratio is at 25.83. MEDCL is valued rather expensively when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 40.91 |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
- MEDCL's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
- A more expensive valuation may be justified as MEDCL's earnings are expected to grow with 47.87% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y66.38%
EPS Next 3Y47.87%
5. Dividend
5.1 Amount
- MEDCL does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
MEDINCELL SA / MEDCL.PA FAQ
What is the ChartMill fundamental rating of MEDINCELL SA (MEDCL.PA) stock?
ChartMill assigns a fundamental rating of 4 / 10 to MEDCL.PA.
Can you provide the valuation status for MEDINCELL SA?
ChartMill assigns a valuation rating of 2 / 10 to MEDINCELL SA (MEDCL.PA). This can be considered as Overvalued.
What is the profitability of MEDCL stock?
MEDINCELL SA (MEDCL.PA) has a profitability rating of 1 / 10.
What is the earnings growth outlook for MEDINCELL SA?
The Earnings per Share (EPS) of MEDINCELL SA (MEDCL.PA) is expected to grow by 59.91% in the next year.